A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Registration Number
- jRCT2061230110
- Lead Sponsor
- F. Hoffmann-La Roche Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 1150
Eastern Cooperative Oncology Group performance status of 0 or 1 Histological or cytological diagnosis of Stage IIB, IIIA, and select IIIB NSCLC of either non-squamous or squamous histology Participants must have had complete resection of NSCLC Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy Participants must have recovered adequately from surgery and from adjuvant chemotherapy Tumor cell PD-L1 expression at >/= 1% Adequate hematologic and end-organ function
Any history of prior NSCLC within the last 5 years Any evidence of residual disease or disease recurrence following surgical resection of NSCLC, or during or following adjuvant chemotherapy NSCLC known to have mutation in the EGFR gene or an ALK fusion oncogene
Study & Design
- Study Type
- Interventional
- Study Design
- parallel assignment
- Primary Outcome Measures
Name Time Method - efficacy
Observation/Inspection
- Secondary Outcome Measures
Name Time Method